Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must satisfy the following criteria to be enrolled in the study:~1. Subject has a diagnosis of Palmoplantar Pustulosis with or without pustulotic arthro-osteitis (PAO) for at least 24 weeks before screening.~2. Subject has a total score of PPPASI: ≥ 12 at screening and baseline.~3. Subject has moderate or severe pustules/vesicles on palms or soles (PPPASI severity score: ≥ 2) at screening and baseline.~4. Subject has inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations prior to or at screening.~Exclusion Criteria:~The presence of any of the following will exclude a subject from enrollment:~1. Subject has a diagnosis of plaque-type psoriasis.~2. Subject has the presence of pustular psoriasis in any part of the body other than the palms and soles.~3. Subject has obvious improvement during screening (≥ 5 PPPASI total score improvement during the screening).~4. Subject has received any procedures for focal infection (e.g, tonsillectomy and dental therapy) within 24 weeks of baseline.~5. Subject has periodontitis obviously requiring treatment at screening.~6. Subject has chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment for a month or more at screening.~7. Subject has evidence of skin conditions of hands and feet that would interfere with evaluations of the effect of study medication.~8. Subject is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo then Apremilast 30mg BID (Type: EXPERIMENTAL): Participants received matched placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
- Apremilast 30 mg BID then Apremilast 30 mg BID (Type: EXPERIMENTAL): Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).

Based on this trial design, predict the completion outcome and termination type (if applicable).